| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neuroscience Research Unit, Center Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
Hepatic encephalopathy (HE) is a neuropsychiatric disorder that occurs in both acute and chronic liver failure. Although the precise pathophysiologic mechanisms responsible for HE are not completely understood, a deficit in neurotransmission rather than a primary deficit in cerebral energy metabolism appears to be involved. The neural cell most vulnerable to liver failure is the astrocyte. In acute liver failure, the astrocyte undergoes swelling resulting in increased intracranial pressure; in chronic liver failure, the astrocyte undergoes characteristic changes known as Alzheimer type II astrocytosis. In portal-systemic encephalopathy resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including monoamine oxidase B, glutamine synthetase, and the so-called peripheral-type benzodiazepine receptors. In addition, expression of some neuroneal proteins such as monoamine oxidase A and neuronal nitric oxide synthase are modified. In acute liver failure, expression of the astrocytic glutamate transporter GLT-1 is reduced, leading to increased extracellular concentrations of glutamate. Many of these changes have been attributed to a toxic effect of ammonia and/or manganese, two substances that are normally removed by the hepatobiliary route and that in liver failure accumulate in the brain. Manganese deposition in the globus pallidus in chronic liver failure results in signal hyperintensity on T1-weighted Magnetic Resonance Imaging and may be responsible for the extrapyramidal symptoms characteristic of portal-systemic encephalopathy. Other neurotransmitter systems implicated in the pathogenesis of hepatic encephalopathy include the serotonin system, where a synaptic deficit has been suggested, as well as the catecholaminergic and opioid systems. Further elucidation of the precise nature of these alterations could result in the design of novel pharmacotherapies for the prevention and treatment of hepatic encephalopathy.
This article has been cited by other articles:
|
|
 |
|
  H. M. ELGOUHARI and R. O'SHEA Q: What is the utility of measuring the serum ammonia level in patients with altered mental status? Cleveland Clinic Journal of Medicine, April 1, 2009; 76(4): 252 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Jayakumar, M. Liu, M. Moriyama, R. Ramakrishnan, B. Forbush III, P. V. B. Reddy, and M. D. Norenberg Na-K-Cl Cotransporter-1 in the Mechanism of Ammonia-induced Astrocyte Swelling J. Biol. Chem., December 5, 2008; 283(49): 33874 - 33882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Crone, G. M. Gabriel, and A. DiMartini An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist Psychosomatics, June 1, 2006; 47(3): 188 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Bhatia, R Singh, and S K Acharya Predictive value of arterial ammonia for complications and outcome in acute liver failure Gut, January 1, 2006; 55(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Matsusue, T. Kinoshita, E. Ohama, and T. Ogawa Cerebral Cortical and White Matter Lesions in Chronic Hepatic Encephalopathy: MR-Pathologic Correlations AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 347 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Veauvy, Y. Wang, P. J. Walsh, and M. A. Perez-Pinzon Comparison of the effects of ammonia on brain mitochondrial function in rats and gulf toadfish Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2002; 283(3): R598 - R603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Oliviero, R Gaspari, P A Tonali, M A Pennisi, G Mercurio, F Pilato, R Proietti, and V Di Lazzaro Changes in excitability of motor cortex in severe hepatic failure J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 414 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Strain and J. M. Neuberger A Bioartificial Liver--State of the Art Science, February 8, 2002; 295(5557): 1005 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. MITZNER, J. STANGE, S. KLAMMT, P. PESZYNSKI, R. SCHMIDT, and G. NOLDGE-SCHOMBURG Extracorporeal Detoxification Using the Molecular Adsorbent Recirculating System for Critically Ill Patients with Liver Failure J. Am. Soc. Nephrol., February 1, 2001; 12(90001): S75 - S82. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
